Inpharmatica has bolstered the discovery side of its hybrid bioinformatics/drug discovery business model by appointing Andrew Ayscough as director of chemistry. Ayscough was previously director of research at British Biotech Pharmaceuticals. The company has also recruited a team of seven medicinal chemists from Millennium Pharmaceuticals.
Steve Trevisan, executive vice president and a director of Gene Logic, will step down, but will continue “in an advisory capacity” until the end of the year, the company said. Trevisan joined Gene Logic in April as part of its acquisition of Therimmune Research, where he was president and CEO.
Thomson ISI has named Francis Collins, Eric Lander, and Craig Venter among its 2003 Citation Laureates — authors of the most frequently cited papers as measured by ISI’s Citation Indexing process and therefore “potential Nobel Prize winners in 2003, or after,” according to the company. The 2003 Nobel Prizes will be announced on Oct. 6.